EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Paroxysmal nocturnal hemoglobinuria: Where we stand

Jens Panse iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26832 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Jens Panse. Beteiligte Einrichtung: Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Apellis Pharmaceuticals, Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For the last 20 years, therapy of paroxysmal nocturnal hemoglobinuria (PNH) relied—up until recently—on antibody based terminal complement inhibitionon. PNH pathophysiology—a mutational defect leading to partial or complete absence of complement‐regulatory proteins on blood cells—leads to intravascular hemolysis and consequences such as thrombosis and other sequelae. A plethora of new drugs interfering with the proximal and terminal complement cascade are under recent development and the first “proof‐of‐pinciple” proximal complement inhibitor targeting C3 has been approved in 2021. “PNH: where we stand” will try to give a brief account on where we came from and where we stand focusing on approved therapeutic options. The associated improvements as well as potential consequences of actual and future treatments as well as their impact on the disease will continue to necessitate academic and scientific focus on improving treatment options as well as on side effects and outcomes relevant to individual patient lives and circumstances in order to develop effective, safe, and available treatment for all hemolytic PNH patients globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansAntibodies, Monoclonal, HumanizedComplement ActivationComplement Inactivating AgentsHemolysis

Substanzen

Antibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
  • Center for Integrated Oncology (CIO), Aachen Bonn Cologne Düsseldorf (ABCD), Aachen, Germany.

ORCID-Profile: Jens Panse

Förderung

  • Apellis Pharmaceuticals
  • Swedish Orphan Biovitrum

Zitieren

APA

Panse, J. (2023). Paroxysmal nocturnal hemoglobinuria: Where we stand. American Journal of Hematology. https://doi.org/10.1002/ajh.26832

Vancouver

Panse J. Paroxysmal nocturnal hemoglobinuria: Where we stand. American Journal of Hematology. 2023. doi:10.1002/ajh.26832

BibTeX
@article{Panse2023,
  author = {Panse, Jens},
  title = {Paroxysmal nocturnal hemoglobinuria: Where we stand},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26832}
}
Kostenlos starten →